Mary Ann Liebert: Using Machine Learning to Identify Patients With Cancer That Would Benefit From Immunotherapy
April 17, 2024
April 17, 2024
NEW ROCHELLE, New York, April 17 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen. The digital pathology approach presented can characterize and classify cancer immunophenotypes in a reproducible and scalable fashion, holding promise for the application of such a. method to identify patients that may benefit from immunotherapy in non-small cell . . .
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen. The digital pathology approach presented can characterize and classify cancer immunophenotypes in a reproducible and scalable fashion, holding promise for the application of such a. method to identify patients that may benefit from immunotherapy in non-small cell . . .